Table 1.
Characteristic of SPLC patients presenting with SCLC and adenocarcinoma
| Sex Age | BI | Diagnosis | Tumor location for SCLC/Ad | Specimen | Treatment for SCLC/Ad | Survival/cause of death | EGFR mutation | ||
|---|---|---|---|---|---|---|---|---|---|
| 1 | Kodama, et al. 1985 | M 55 | 1400 | SCLC Papillary Ad | Right upper/ Right lower | Bronchoscopy/ Percutaneous | Right pnemonectomy | 5 months, dead Dermatomyositis Interstitial pneumonia | ND |
| 2 | Hida, et al. 1993 | M 63 | 1200 | SCLC Moderately differentiated Ad | Right lower/ Right upper | TBLB | Cisplatin + doxorubicin + cyclophosphamide + etposide/Thoracic RT (50 Gy) | 9 months, dead Heart attack | ND |
| 3 | Hiraki, et al. 1999 | M 57 | 1800 | SCLC Moderately differentiated Ad | Subcarinal LN/Right upper | LN biopsy TBLB | Cisplatin + etoposide + thoracic RT (50 Gy)/ Thoracioscopic partial resection | 13 months, alive SCLC recurrence | ND |
| 4 | Kobashi, et al. 2006 | M 73 | 500 | SCLC Well differentiated Ad | Left upper (S1+2)/Left upper (S3) | TBLB | Cisplatin + Irinotecan/ Left upper lobectomy | 3 months, alive No recurrence | ND |
| 5 | Norkowski, et al. 2013 | F 65 | 900 | SCLC Well differentiated Acinar and papillary Ad | Left upper (S1+2)/Left upper (S3) | Resection | ND | ND | SCLC none Upper lobe Ad: none Lower lobe Ad: exson 21 L858R |
| 6 | Present Case 1 | M 70 | 2040 | SCLC Minimally invasive Ad | Right hilar LN/Right lower (S10) | Resection | Carboplatin + etoposide/Right lower lobectomy | 12 months, alive No recurrence | SCLC: none Ad: none |
| 7 | Present Case 2 | M 72 | 2000 | SCLC Ad in situ | Right hilar LN/Right lower (S6) | Resection | Carboplatin + etoposide/Right lower lobectomy | 10 months, alive No recurrence | SCLC: none Ad: none |
SPLC: synchronous primary lung cancer; BI: Brinkman index; SCLC: small cell lung cancer; Ad: adenocarcinoma; EGFR: epidermal growth factor receptor; TBLB: transbronchial lung biopsy; ND: not described; RT: radiation therapy; LN: lymph node